Skip to Content


M. D. Anderson Announces Collaboration with the Premier French Cancer Institution

M. D. Anderson Announces Collaboration with the Premier French Cancer Institution
M. D. Anderson News Release, 02/09/2004

The University of Texas M. D. Anderson Cancer Center and Institut Gustave Roussy in Villejuif, France, two of the world’s premier cancer institutions, announced today an agreement to expand opportunities for collaboration in clinical, educational and cancer research fields.  The agreement, which builds upon long-term professional relationships between physicians and scientists at both institutions, formalizes a framework for cooperation and represents a step forward in the global fight against cancer.

Representatives of both institutions participated in a signing ceremony at the Institut Gustave Roussy, which also was attended by Howard H. Leach, the United States Ambassador to France.  The new sister institution agreement encompasses both institutions’ leading clinical disciplines – including prevention, medicine, surgery, radiology, radiation oncology and pathology – as well as translational research programs and basic research laboratories.  The institutions also anticipate working together on some patient care services, including diagnosis and consultation on patients with rare malignancies.

M. D. Anderson and Institut Gustave Roussy are internationally renowned for their commitment to translational medicine – driving pioneering cancer research from the laboratory to patient therapies at the bedside – and are dedicated to the highest standards of clinical care, education and prevention.  The institutions currently are working on a joint study exploring the treatment of testicular cancer.

Thomas Brown, M.D., vice president for extramural programs at M. D. Anderson, said that the sister agreement reflects the shared mission of M. D. Anderson and Institut Gustave Roussy to pursue research-driven patient care at the global level.  “It is an honor to engage collaboratively in our quest to eradicate cancer with an institution of Gustave Roussy’s prestige and reputation.  Our goals and medical/scientific cultures are similar, driven by our fundamental interest in advancing scientific discovery, together, through focused projects in translational research.”

Professor Thomas Tursz, director of the Institut Gustave Roussy, added, “This agreement extends the important cooperation that has existed over many years between the Institut Gustave Roussy and M. D. Anderson Cancer Center, and further enhances the ability of both institutions to identify additional areas of academic collaboration and knowledge exchange that will benefit patients and lead to greater scientific insights into curing cancer.”

Initially, the institutions will focus on research into endocrine malignancies, particularly of the thyroid, which builds on work currently under way by teams at M. D. Anderson and Institut Gustave Roussy, and plan clinical trials for the multidisciplinary care of lung cancer.

Further, in addition to exploring other possible joint clinical trials, the institutions have identified a number of areas of possible collaboration and exchange, including: organizing scientific meetings and inviting delegations of clinicians and researchers to specific symposia; fostering the exchange of clinical databases, creating visiting professor positions; supporting post-doctoral training and fellowship programs; and sharing experience in the nursing field.   

M. D. Anderson – Making Cancer History

M. D. Anderson, a nonprofit institution founded in 1941, has established an international reputation as one of the world’s preeminent centers for cancer patient care, research, education and prevention.  A multidisciplinary approach, and dedication to translational research, education and prevention are hallmarks of M. D. Anderson.  Looking to the future, M. D. Anderson is increasingly focused on sharing new research developments and clinical expertise through affiliations with premier institutions around the world. M. D. Anderson Cancer Center was designated by the National Cancer Institute (NCI) as one of the first three Comprehensive Cancer Centers in the United States. Consistently ranked one of the top two cancer centers in the United States by U.S. News & World Report’s “America’s Best Hospitals” – including number one in three of the past four years – M. D. Anderson has provided care for more than 600,000 cancer patients since 1944 and 65,000 in the last year alone.  In 2003, nearly 1,000 new patients from outside the U.S. came to M. D. Anderson for care.  M. D. Anderson faculty currently hold more NCI research grants and grant dollars than any other academic center in the U.S.

Institut Gustave Roussy – In the Heart of 21st – century Oncology

Institut Gustave Roussy, the leading European Comprehensive Anticancer Center has a staff of 2,350 persons on the same site, whose missions are patient care, research and the development of new treatments and the transmission of knowledge to the medical and scientific community in France and throughout the world.  In a 400-bed hospital, the medical teams see 11,000 new patients, conduct 130,000 consultations and treat 42,000 patients annually.  Research is carried out by 300 research scientists under the supervision of a Scientific Council. More than 400 articles are published annually in peer-reviewed medical and scientific journals.  Teaching takes place in its School of Oncology, in the Doctoral School of Oncology and in the Institute of Advanced Biomedical Education. More than 5,000 hours are taught in collaboration with the University of Paris XI Medical School.  At the gateway to Paris, IGR is on the verge of creating the leading French Center for Research and Treatment of Cancer with partnerships in the public and private sectors.  Determined that patients may benefit from the most recent innovative cancer treatments, IGR is the strongest link in the transfer of scientific discoveries from the bench to the bedside.


© 2015 The University of Texas MD Anderson Cancer Center